Epithelial Ovarian Cancer (EOC) is the most lethal gynaecological malignancy due to the advanced stage at diagnosis and the development of drug-resistant recurrences after a good initial response to the therapy based on platinum drugs. Alterations of different cellular pathways, such as DNA repair, apoptosis and p53, have been identified as linked to the onset of platinum resistance in ovarian cancer. We performed a high-throughput shRNA-based screening to identify genes whose suppression enhanced cell sensitivity to platinum drug in different EOC cell lines (synthetic lethality). Bioinformatics analysis and a subsequent validation screening identified 8 genes possibly involved in platinum response. Our aim was to dissect the role of one of...
Epithelial ovarian cancer is one of the most common gynecological malignancies and the fifth most fr...
Background The present study is aimed to identify genetic pathways correlated with chemoresistance ...
Background: Failure to respond to treatment in epithelial ovarian cancer can often be attributed to ...
Background: Ovarian cancer is the leading cause of gynecologic cancer-related death, due in part to ...
Epithelial ovarian cancer (EOC), the most lethal gynecological malignancy, is normally treated with ...
embargoed_20230303High Grade Epithelial Ovarian Cancers (HGEOCs) is a heterogeneous group of tumours...
Ovarian cancer is the leading cause of gynecologic cancer-related death, due in part to a late diagn...
Resistance to platinum chemotherapy regimens represents a major obstacle in the successful treatment...
Standard of care for Epithelial Ovarian Cancer (EOC) patients relies on platinum-based therapy. Howe...
Investigating AMPK signalling regulation of autophagy in a model of ovarian tumour dormancy Jeremi L...
Molecular targeted therapies have been the focus of recent clinical trials for the treatment of pati...
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women. Two-thir...
Introduction: Ovarian Cancer is the most lethal gynaecologic malignancy, with epithelial ovarian can...
Epithelial ovarian cancer is one of the most common gynecological malignancies and the fifth most fr...
AbstractObjectiveOvarian cancers are highly heterogeneous and while chemotherapy is the preferred tr...
Epithelial ovarian cancer is one of the most common gynecological malignancies and the fifth most fr...
Background The present study is aimed to identify genetic pathways correlated with chemoresistance ...
Background: Failure to respond to treatment in epithelial ovarian cancer can often be attributed to ...
Background: Ovarian cancer is the leading cause of gynecologic cancer-related death, due in part to ...
Epithelial ovarian cancer (EOC), the most lethal gynecological malignancy, is normally treated with ...
embargoed_20230303High Grade Epithelial Ovarian Cancers (HGEOCs) is a heterogeneous group of tumours...
Ovarian cancer is the leading cause of gynecologic cancer-related death, due in part to a late diagn...
Resistance to platinum chemotherapy regimens represents a major obstacle in the successful treatment...
Standard of care for Epithelial Ovarian Cancer (EOC) patients relies on platinum-based therapy. Howe...
Investigating AMPK signalling regulation of autophagy in a model of ovarian tumour dormancy Jeremi L...
Molecular targeted therapies have been the focus of recent clinical trials for the treatment of pati...
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women. Two-thir...
Introduction: Ovarian Cancer is the most lethal gynaecologic malignancy, with epithelial ovarian can...
Epithelial ovarian cancer is one of the most common gynecological malignancies and the fifth most fr...
AbstractObjectiveOvarian cancers are highly heterogeneous and while chemotherapy is the preferred tr...
Epithelial ovarian cancer is one of the most common gynecological malignancies and the fifth most fr...
Background The present study is aimed to identify genetic pathways correlated with chemoresistance ...
Background: Failure to respond to treatment in epithelial ovarian cancer can often be attributed to ...